JP2008517042A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008517042A5 JP2008517042A5 JP2007537324A JP2007537324A JP2008517042A5 JP 2008517042 A5 JP2008517042 A5 JP 2008517042A5 JP 2007537324 A JP2007537324 A JP 2007537324A JP 2007537324 A JP2007537324 A JP 2007537324A JP 2008517042 A5 JP2008517042 A5 JP 2008517042A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- alkoxy
- thiazol
- amide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 12
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 8
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 8
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 8
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims description 8
- 125000000355 1,3-benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 4
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims description 4
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 claims description 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 4
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 33
- 229910052736 halogen Inorganic materials 0.000 claims 16
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 14
- 150000002367 halogens Chemical class 0.000 claims 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 12
- 125000005843 halogen group Chemical group 0.000 claims 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 6
- 125000000815 N-oxide group Chemical group 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 6
- 150000007513 acids Chemical class 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 150000004677 hydrates Chemical class 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- BOQOXLAQTDFJKU-UHFFFAOYSA-N morpholine-4-carbonitrile Chemical compound N#CN1CCOCC1 BOQOXLAQTDFJKU-UHFFFAOYSA-N 0.000 claims 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- SRUSSDUBONXALX-UHFFFAOYSA-N N-[4-(5-cyclohexyl-2-methoxyphenyl)-1,3-thiazol-2-yl]piperidine-3-carboxamide Chemical compound C1(CCCCC1)C=1C=CC(=C(C=1)C=1N=C(SC=1)NC(=O)C1CNCCC1)OC SRUSSDUBONXALX-UHFFFAOYSA-N 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000001786 isothiazolyl group Chemical group 0.000 claims 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 3
- 125000002971 oxazolyl group Chemical group 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims 3
- 125000000335 thiazolyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- MVHAQXYRERDMGX-UHFFFAOYSA-N N-[4-(5-cyclohexyl-2-methoxyphenyl)-1,3-thiazol-2-yl]pyrrolidine-3-carboxamide Chemical compound COC1=CC=C(C2CCCCC2)C=C1C(N=1)=CSC=1NC(=O)C1CCNC1 MVHAQXYRERDMGX-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 125000005336 allyloxy group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- UZGCRIGUQOVVFR-HXUWFJFHSA-N (3r)-n-[4-(5-cyclohexyl-2-methoxyphenyl)-1,3-thiazol-2-yl]-1-(pyrazine-2-carbonyl)piperidine-3-carboxamide Chemical compound C([C@H](C1)C(=O)NC=2SC=C(N=2)C2=CC(=CC=C2OC)C2CCCCC2)CCN1C(=O)C1=CN=CC=N1 UZGCRIGUQOVVFR-HXUWFJFHSA-N 0.000 claims 1
- UZGCRIGUQOVVFR-FQEVSTJZSA-N (3s)-n-[4-(5-cyclohexyl-2-methoxyphenyl)-1,3-thiazol-2-yl]-1-(pyrazine-2-carbonyl)piperidine-3-carboxamide Chemical compound C([C@@H](C1)C(=O)NC=2SC=C(N=2)C2=CC(=CC=C2OC)C2CCCCC2)CCN1C(=O)C1=CN=CC=N1 UZGCRIGUQOVVFR-FQEVSTJZSA-N 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- GJYGAFGYZQSTMH-UHFFFAOYSA-N 1-(5-chloro-1-methylpyrazole-4-carbonyl)-n-[4-(5-cyclohexyl-2-methoxyphenyl)-1,3-thiazol-2-yl]piperidine-3-carboxamide Chemical compound COC1=CC=C(C2CCCCC2)C=C1C(N=1)=CSC=1NC(=O)C(C1)CCCN1C(=O)C=1C=NN(C)C=1Cl GJYGAFGYZQSTMH-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- -1 Boc group Chemical group 0.000 claims 1
- KPUVQTHFXBMWQV-UHFFFAOYSA-N N-[4-(5-butyl-2-methoxyphenyl)-1,3-thiazol-2-yl]piperidine-3-carboxamide Chemical compound C(CCC)C=1C=CC(=C(C=1)C=1N=C(SC=1)NC(=O)C1CNCCC1)OC KPUVQTHFXBMWQV-UHFFFAOYSA-N 0.000 claims 1
- UTQIURRSMLULQB-UHFFFAOYSA-N N-[4-(5-cyclopentyl-2-methoxyphenyl)-1,3-thiazol-2-yl]piperidine-3-carboxamide Chemical compound C1(CCCC1)C=1C=CC(=C(C=1)C=1N=C(SC=1)NC(=O)C1CNCCC1)OC UTQIURRSMLULQB-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000007822 coupling agent Substances 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000000495 immunoinflammatory effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- POAIOYTYGFGBOY-UHFFFAOYSA-N n-[4-(5-cyclohexyl-2-ethoxyphenyl)-1,3-thiazol-2-yl]-1-(pyrazine-2-carbonyl)piperidine-3-carboxamide Chemical compound CCOC1=CC=C(C2CCCCC2)C=C1C(N=1)=CSC=1NC(=O)C(C1)CCCN1C(=O)C1=CN=CC=N1 POAIOYTYGFGBOY-UHFFFAOYSA-N 0.000 claims 1
- KZJNCUDYCCMESU-UHFFFAOYSA-N n-[4-(5-cyclohexyl-2-methoxyphenyl)-1,3-thiazol-2-yl]-1-(1,5-dimethylpyrazole-3-carbonyl)piperidine-3-carboxamide Chemical compound COC1=CC=C(C2CCCCC2)C=C1C(N=1)=CSC=1NC(=O)C(C1)CCCN1C(=O)C=1C=C(C)N(C)N=1 KZJNCUDYCCMESU-UHFFFAOYSA-N 0.000 claims 1
- UGAMCDRWOXXFRA-UHFFFAOYSA-N n-[4-(5-cyclohexyl-2-methoxyphenyl)-1,3-thiazol-2-yl]-1-(1-methylimidazole-2-carbonyl)piperidine-3-carboxamide Chemical compound COC1=CC=C(C2CCCCC2)C=C1C(N=1)=CSC=1NC(=O)C(C1)CCCN1C(=O)C1=NC=CN1C UGAMCDRWOXXFRA-UHFFFAOYSA-N 0.000 claims 1
- AEXQESOTSPPIIR-UHFFFAOYSA-N n-[4-(5-cyclohexyl-2-methoxyphenyl)-1,3-thiazol-2-yl]-1-(2-oxo-1h-pyridine-3-carbonyl)piperidine-3-carboxamide Chemical compound COC1=CC=C(C2CCCCC2)C=C1C(N=1)=CSC=1NC(=O)C(C1)CCCN1C(=O)C1=CC=CN=C1O AEXQESOTSPPIIR-UHFFFAOYSA-N 0.000 claims 1
- DISBKTYXVGZBQY-UHFFFAOYSA-N n-[4-(5-cyclohexyl-2-methoxyphenyl)-1,3-thiazol-2-yl]-1-(2-pyridin-2-ylacetyl)piperidine-3-carboxamide Chemical compound COC1=CC=C(C2CCCCC2)C=C1C(N=1)=CSC=1NC(=O)C(C1)CCCN1C(=O)CC1=CC=CC=N1 DISBKTYXVGZBQY-UHFFFAOYSA-N 0.000 claims 1
- KEFVPSJTLZONNL-UHFFFAOYSA-N n-[4-(5-cyclohexyl-2-methoxyphenyl)-1,3-thiazol-2-yl]-1-(furan-2-carbonyl)piperidine-3-carboxamide Chemical compound COC1=CC=C(C2CCCCC2)C=C1C(N=1)=CSC=1NC(=O)C(C1)CCCN1C(=O)C1=CC=CO1 KEFVPSJTLZONNL-UHFFFAOYSA-N 0.000 claims 1
- AEEPZDSCOILTDI-UHFFFAOYSA-N n-[4-(5-cyclohexyl-2-methoxyphenyl)-1,3-thiazol-2-yl]-1-(pyrazine-2-carbonyl)piperidine-2-carboxamide Chemical compound COC1=CC=C(C2CCCCC2)C=C1C(N=1)=CSC=1NC(=O)C1CCCCN1C(=O)C1=CN=CC=N1 AEEPZDSCOILTDI-UHFFFAOYSA-N 0.000 claims 1
- UZGCRIGUQOVVFR-UHFFFAOYSA-N n-[4-(5-cyclohexyl-2-methoxyphenyl)-1,3-thiazol-2-yl]-1-(pyrazine-2-carbonyl)piperidine-3-carboxamide Chemical compound COC1=CC=C(C2CCCCC2)C=C1C(N=1)=CSC=1NC(=O)C(C1)CCCN1C(=O)C1=CN=CC=N1 UZGCRIGUQOVVFR-UHFFFAOYSA-N 0.000 claims 1
- LKIZXBUWQPNTQF-UHFFFAOYSA-N n-[4-(5-cyclohexyl-2-methoxyphenyl)-1,3-thiazol-2-yl]-1-(pyrazine-2-carbonyl)piperidine-4-carboxamide Chemical compound COC1=CC=C(C2CCCCC2)C=C1C(N=1)=CSC=1NC(=O)C(CC1)CCN1C(=O)C1=CN=CC=N1 LKIZXBUWQPNTQF-UHFFFAOYSA-N 0.000 claims 1
- DEEOSPIQFYSNIA-UHFFFAOYSA-N n-[4-(5-cyclohexyl-2-methoxyphenyl)-1,3-thiazol-2-yl]-1-(pyrimidine-4-carbonyl)piperidine-3-carboxamide Chemical compound COC1=CC=C(C2CCCCC2)C=C1C(N=1)=CSC=1NC(=O)C(C1)CCCN1C(=O)C1=CC=NC=N1 DEEOSPIQFYSNIA-UHFFFAOYSA-N 0.000 claims 1
- GCNRKXBJZHYOQD-UHFFFAOYSA-N n-[4-(5-cyclopentyl-2-methoxyphenyl)-1,3-thiazol-2-yl]-1-(pyrazine-2-carbonyl)piperidine-3-carboxamide Chemical compound COC1=CC=C(C2CCCC2)C=C1C(N=1)=CSC=1NC(=O)C(C1)CCCN1C(=O)C1=CN=CC=N1 GCNRKXBJZHYOQD-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0411083A FR2876692B1 (fr) | 2004-10-19 | 2004-10-19 | Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique |
| PCT/FR2005/002565 WO2006042954A1 (fr) | 2004-10-19 | 2005-10-17 | Dérivés de 2-amido-4-phenylthiazole, leur préparation et leur application en thérapeutique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008517042A JP2008517042A (ja) | 2008-05-22 |
| JP2008517042A5 true JP2008517042A5 (enExample) | 2012-01-19 |
Family
ID=34950743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007537324A Pending JP2008517042A (ja) | 2004-10-19 | 2005-10-17 | ２−アミド−４−フェニルチアゾール誘導体、その調製及び治療的使用 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7598392B2 (enExample) |
| EP (1) | EP1807421B1 (enExample) |
| JP (1) | JP2008517042A (enExample) |
| KR (1) | KR20070085395A (enExample) |
| CN (1) | CN101065376A (enExample) |
| AR (1) | AR051334A1 (enExample) |
| AT (1) | ATE502035T1 (enExample) |
| AU (1) | AU2005296958A1 (enExample) |
| BR (1) | BRPI0518231A2 (enExample) |
| CA (1) | CA2584774A1 (enExample) |
| DE (1) | DE602005026964D1 (enExample) |
| EA (1) | EA200700901A1 (enExample) |
| EC (1) | ECSP077402A (enExample) |
| FR (1) | FR2876692B1 (enExample) |
| GT (1) | GT200500292A (enExample) |
| IL (1) | IL182624A0 (enExample) |
| MA (1) | MA29017B1 (enExample) |
| MX (1) | MX2007004740A (enExample) |
| NO (1) | NO20072515L (enExample) |
| PA (1) | PA8649901A1 (enExample) |
| PE (1) | PE20060585A1 (enExample) |
| SV (1) | SV2006002274A (enExample) |
| TN (1) | TNSN07145A1 (enExample) |
| TW (1) | TW200630364A (enExample) |
| UY (1) | UY29169A1 (enExample) |
| WO (1) | WO2006042954A1 (enExample) |
| ZA (1) | ZA200703876B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2854158B1 (fr) | 2003-04-25 | 2006-11-17 | Sanofi Synthelabo | Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique |
| FR2872813B1 (fr) | 2004-07-09 | 2007-01-19 | Sanofi Synthelabo | Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique |
| RU2008128453A (ru) | 2005-12-12 | 2010-01-20 | Дженелабс Текнолоджис, Инк. (Us) | Соединение n-(5-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения |
| FR2895989B1 (fr) | 2006-01-06 | 2010-04-30 | Sanofi Aventis | Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique |
| US20100331298A1 (en) * | 2007-12-10 | 2010-12-30 | Cytopathfinder, Inc. | Carboxamide Compounds and Their Use |
| AU2008335135A1 (en) | 2007-12-11 | 2009-06-18 | Cytopathfinder, Inc. | Carboxamide compounds and their use as chemokine receptor agonists |
| EP2349484A2 (en) | 2008-07-15 | 2011-08-03 | Novartis AG | Heteroaryl derivatives as dgat1 inhibitors |
| JP5819730B2 (ja) * | 2008-12-22 | 2015-11-24 | ケモセントリックス，インコーポレイティド | Ｃ５ａＲアンタゴニスト |
| CN103402996B (zh) | 2011-01-04 | 2015-02-11 | 诺瓦提斯公司 | 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物 |
| JP6209605B2 (ja) | 2012-06-28 | 2017-10-04 | ノバルティス アーゲー | ピロリジン誘導体、および補体経路調節因子としてのその使用 |
| CN104619698B (zh) | 2012-06-28 | 2016-08-31 | 诺华股份有限公司 | 吡咯烷衍生物及其作为补体途径调节剂的用途 |
| WO2014002051A2 (en) | 2012-06-28 | 2014-01-03 | Novartis Ag | Complement pathway modulators and uses thereof |
| CN104640855B (zh) | 2012-06-28 | 2017-08-29 | 诺华股份有限公司 | 补体途经调节剂及其用途 |
| EP2867229B1 (en) | 2012-06-28 | 2017-07-26 | Novartis AG | Pyrrolidine derivatives and their use as complement pathway modulators |
| US9550755B2 (en) | 2012-07-12 | 2017-01-24 | Novartis Ag | Complement pathway modulators and uses thereof |
| AR121506A1 (es) | 2020-03-03 | 2022-06-08 | Pic Therapeutics Inc | Inhibidores del eif4e y sus usos |
| US12157732B2 (en) | 2021-08-25 | 2024-12-03 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
| IL310924A (en) | 2021-08-25 | 2024-04-01 | Pic Therapeutics Inc | Eif4e inhibitors and uses thereof |
| KR20240140019A (ko) * | 2023-03-15 | 2024-09-24 | 현대약품 주식회사 | 신규한 화합물, 및 이를 포함하는 약학적 조성물 |
| WO2026054614A1 (ko) * | 2024-09-09 | 2026-03-12 | 현대약품 주식회사 | 신규한 화합물, 및 이를 포함하는 약학적 조성물 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2146898A (en) * | 1937-12-06 | 1939-02-14 | Int Harvester Co | Potato digger |
| FR2406634A1 (fr) * | 1977-10-19 | 1979-05-18 | Fabre Sa Pierre | Immunostimulants derives d'amino thiazoles |
| FR2677356B1 (fr) | 1991-06-05 | 1995-03-17 | Sanofi Sa | Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant. |
| EP0589985A1 (en) | 1991-06-21 | 1994-04-06 | Boehringer Mannheim Italia S.P.A. | 2-amino-4-aryl-thiazoles with antiasthmatic and anti-inflammatory activities on the respiratory tract |
| US6506751B1 (en) * | 1999-11-12 | 2003-01-14 | Millennium Pharmaceuticals, Inc. | Thiazolidinone compounds useful as chemokine inhibitors |
| US6852752B2 (en) * | 1999-12-17 | 2005-02-08 | Vicuron Pharmaceuticals Inc. | Urea compounds, compositions and methods of use and preparation |
| US6797820B2 (en) * | 1999-12-17 | 2004-09-28 | Vicuron Pharmaceuticals Inc. | Succinate compounds, compositions and methods of use and preparation |
| CN1289072C (zh) * | 2000-12-22 | 2006-12-13 | 石原产业株式会社 | 苯胺衍生物或其盐以及含有它们的细胞因子产生抑制剂 |
| US7265134B2 (en) | 2001-08-17 | 2007-09-04 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| FR2854158B1 (fr) * | 2003-04-25 | 2006-11-17 | Sanofi Synthelabo | Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique |
| TW200423931A (en) | 2003-04-30 | 2004-11-16 | Hoffmann La Roche | Novel aniline derivatives, their manufacture and use as pharmaceutical agents |
| FR2872813B1 (fr) * | 2004-07-09 | 2007-01-19 | Sanofi Synthelabo | Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique |
| CA2589748C (en) | 2004-12-24 | 2013-08-13 | Astrazeneca Ab | Heterocyclic compounds as ccr2b antagonists |
| FR2895989B1 (fr) | 2006-01-06 | 2010-04-30 | Sanofi Aventis | Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique |
-
2004
- 2004-10-19 FR FR0411083A patent/FR2876692B1/fr not_active Expired - Fee Related
-
2005
- 2005-10-17 AT AT05809089T patent/ATE502035T1/de not_active IP Right Cessation
- 2005-10-17 EA EA200700901A patent/EA200700901A1/ru unknown
- 2005-10-17 CN CNA2005800396968A patent/CN101065376A/zh active Pending
- 2005-10-17 CA CA002584774A patent/CA2584774A1/fr not_active Abandoned
- 2005-10-17 AU AU2005296958A patent/AU2005296958A1/en not_active Withdrawn
- 2005-10-17 BR BRPI0518231-0A patent/BRPI0518231A2/pt not_active IP Right Cessation
- 2005-10-17 UY UY29169A patent/UY29169A1/es not_active Application Discontinuation
- 2005-10-17 MX MX2007004740A patent/MX2007004740A/es not_active Application Discontinuation
- 2005-10-17 DE DE602005026964T patent/DE602005026964D1/de not_active Expired - Lifetime
- 2005-10-17 ZA ZA200703876A patent/ZA200703876B/xx unknown
- 2005-10-17 KR KR1020077011308A patent/KR20070085395A/ko not_active Withdrawn
- 2005-10-17 WO PCT/FR2005/002565 patent/WO2006042954A1/fr not_active Ceased
- 2005-10-17 GT GT200500292A patent/GT200500292A/es unknown
- 2005-10-17 JP JP2007537324A patent/JP2008517042A/ja active Pending
- 2005-10-17 EP EP05809089A patent/EP1807421B1/fr not_active Expired - Lifetime
- 2005-10-18 AR ARP050104349A patent/AR051334A1/es unknown
- 2005-10-18 TW TW094136365A patent/TW200630364A/zh unknown
- 2005-10-18 PA PA20058649901A patent/PA8649901A1/es unknown
- 2005-10-19 PE PE2005001227A patent/PE20060585A1/es not_active Application Discontinuation
- 2005-10-19 SV SV2005002274A patent/SV2006002274A/es unknown
-
2007
- 2007-04-17 IL IL182624A patent/IL182624A0/en unknown
- 2007-04-18 US US11/736,770 patent/US7598392B2/en not_active Expired - Fee Related
- 2007-04-18 EC EC2007007402A patent/ECSP077402A/es unknown
- 2007-04-19 TN TNP2007000145A patent/TNSN07145A1/fr unknown
- 2007-05-11 MA MA29894A patent/MA29017B1/fr unknown
- 2007-05-16 NO NO20072515A patent/NO20072515L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023514872A5 (enExample) | ||
| KR102276700B1 (ko) | 헤테로사이클릭 유도체 | |
| JP5795402B2 (ja) | 新規抗血小板薬 | |
| JP2018515555A5 (enExample) | ||
| JP2020512343A5 (enExample) | ||
| RU2451674C2 (ru) | Пиридинкарбоксамиды в качестве ингибиторов 11-бета-hsd1 | |
| JP2012503018A5 (enExample) | ||
| JP2006500348A5 (enExample) | ||
| JP2016519096A5 (enExample) | ||
| JP2014001228A (ja) | Ｈ−ｐｇｄｓの阻害剤としてのマルチヘテロアリール化合物及びプロスタグランジンｄ２を介した疾患を治療するための該化合物の使用 | |
| JP2013539777A5 (enExample) | ||
| JP2010529991A5 (enExample) | ||
| JP2019505594A5 (enExample) | ||
| RU2006100190A (ru) | Производные хинолиламида в качестве антагонистов ccr-5 | |
| KR20220050944A (ko) | 효소 저해제 | |
| JP2013542267A5 (enExample) | ||
| JP2011510985A5 (enExample) | ||
| JP2020503302A5 (enExample) | ||
| JP2008513405A5 (enExample) | ||
| JP2008517042A (ja) | ２−アミド−４−フェニルチアゾール誘導体、その調製及び治療的使用 | |
| JP2014521620A5 (enExample) | ||
| JP2019520412A5 (enExample) | ||
| JP2015507004A5 (enExample) | ||
| JP2009503103A (ja) | アリールピリジン及びその使用方法 | |
| JP2016510810A5 (enExample) |